2 results
Approved WMOCompleted
In this research we want to determine whether patients prefer the ProTrach DualCare over other speaking valves, if it improves quality of life, compliance with HME use and lung function.
Approved WMOCompleted
To demonstrate that treatment with drotrecogin alfa (activated) 24 mcg/kg/h administered as an intravenous infusion for 96 hours reduces 28 day all-cause mortality in adult patients with septic shock compared with placebo.